Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COMMENTARY
COMMENTARY
- Range of Drugs Eligible for Premium for New Drug Development May Be Reviewed; Industry Needs to Dispel Suspicions
November 13, 2013
- Interim Report of Diovan Committee Raises Further Questions
October 15, 2013
- Remicade Biosimilar Debut Awaited in FY2014; Good Opportunity to Revisit Healthcare Finance?
October 4, 2013
- Comprehensive Review of Package Inserts to Begin with Effort to Identify Inconsistencies Between Inserts for Similar Drugs
August 27, 2013
- Transparency Guidelines Go Live, Will It Help Pharmas Win Public Trust?
August 2, 2013
- Overseas Outlook Will Be Essential to Survival and Progress of Domestic CROs
June 24, 2013
- PMDA’s Seriousness About Becoming a Leading Global Regulatory Authority to Be Tested
May 30, 2013
- Beyond Risk Management: RMPs Provide Opportunity for Post-Marketing Drug Development and Product Differentiation
May 8, 2013
- Iressa Cases Signal Risks Hiding in Daily Clinical Practices
April 22, 2013
- Will Drugs that Fight Cancer Stem Cells Succeed? Domestic Clinical Trial by DSP on the Horizon
March 15, 2013
- Gov’t, Industry to Support Developing Countries through Development of Drugs for Infectious Diseases; Hoping to Secure Future Business Opportunities as Well
February 27, 2013
- What Next for a “Mature” ICH? What More Can Be Done Beyond Regulatory Harmonization?
January 22, 2013
- Hot Products in 2013: New Drugs Likely to Jolt RA Treatment, Anticoagulant Markets
January 8, 2013
- Counterfeit Drugs: Risks Lurking in Globalization
December 28, 2012
- Can Japan Craft Its Own “Compassionate Use” System without Spoiling Drug Makers’ Development Drives?
December 7, 2012
- Recent Announcements of Suspended Product Supplies Highlight Supply Risks Faced by Generic Drug Industry
November 27, 2012
- Will Integration of Domestic Makers Be Enough for Sustainable Plasma Fractionation Operations?
November 16, 2012
- Approval of Switch-OTC Epadel Puts Spotlight on Quality, Track Record of Pharmacists
November 9, 2012
- Final Preparations Underway for Trial Run of Medical Database
September 25, 2012
- Competition Getting Fiercer in COPD Drug Market
September 13, 2012
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…